Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: J Rheumatol. 2013 Jul 1;40(8):1394–1403. doi: 10.3899/jrheum.121180

Figure 2.

Figure 2

Time-to-treatment success following initiation of Tumor Necrosis Factor-α inhibitors in children with uveitis. The 95% CI is represented by the areas shaded in grey. A. “Slightly active” (trace or fewer AC cells (≤0.5+) or better control of inflammation in all eyes with uveitis absent use of oral corticosteroids and with no more than two drops/day of topical corticosteroids. B. “Slightly active” in children treated with monoclonal antibody anti-TNFα (infliximab or adalimumab) (mAb) vs. those treated with etanercept (non-mAb). C. Complete uveitis inactivity without concomitant topical or oral corticosteroids. D. “Slightly active” or better control of inflammation in different subgroups of children with uveitis; treatment success over time is demonstrated in subgroups determined by their juvenile idiopathic arthritis (JIA) and anterior uveitis (AU) statuses.